Concise Review: Role of Mesenchymal Stem Cells in Wound Repair

SCOTT MAXSON, ERASMO A. LOPEZ, DANA YOO, ALLA DANILKOVITCH-MIAGKOVA, MICHELLE A. LE ROUX

Key Words. Mesenchymal stem cells • Cellular therapy • Placenta • Tissue regeneration

ABSTRACT

Wound healing requires a coordinated interplay among cells, growth factors, and extracellular matrix proteins. Central to this process is the endogenous mesenchymal stem cell (MSC), which coordinates the repair response by recruiting other host cells and secreting growth factors and matrix proteins. MSCs are self-renewing multipotent stem cells that can differentiate into various lineages of mesenchymal origin such as bone, cartilage, tendon, and fat. In addition to multilineage differentiation capacity, MSCs regulate immune response and inflammation and possess powerful tissue protective and reparative mechanisms, making these cells attractive for treatment of different diseases. The beneficial effect of exogenous MSCs on wound healing was observed in a variety of animal models and in reported clinical cases. Specifically, they have been successfully used to treat chronic wounds and stimulate stalled healing processes. Recent studies revealed that human placental membranes are a rich source of MSCs for tissue regeneration and repair. This review provides a concise summary of current knowledge of biological properties of MSCs and describes the use of MSCs for wound healing. In particular, the scope of this review focuses on the role MSCs have in each phase of the wound-healing process. In addition, characterization of MSCs containing skin substitutes is described, demonstrating the presence of key growth factors and cytokines uniquely suited to aid in wound repair.

INTRODUCTION

Nonhealing chronic wounds are a large and growing problem with an incidence of 5–7 million cases per year in the United States [1], and ~50% of those wounds do not respond to current treatments [2]. Accumulated data indicate that wound-care products should have a composition equivalent to that of the skin: a combination of particular growth factors and extracellular matrix (ECM) proteins endogenous to the skin, together with viable epithelial cells, fibroblasts, and mesenchymal stem cells (MSCs). Recently, strategies consisting of bioengineered dressings and cell-based products have emerged for widespread clinical use; however, their performance is not optimal because chronic wounds persist as a serious unmet medical need. The presence of MSCs in normal skin [3] and their critical role in wound healing [4] suggest that the application of exogenous MSCs is a promising solution to treat nonhealing wounds.

MSCs have been well characterized to be multipotent cells that can differentiate into multiple tissue-forming cell lineages, such as osteoblasts, adipocytes, chondrocytes, tenocytes, and myocytes [5, 6]. In addition, they can be readily expanded ex vivo for several passages without losing their self-renewal capacity [7, 8]. In addition to the multilineage differentiation capacity that is useful for regeneration, MSCs regulate immune and inflammatory responses. These functions provide therapeutic potential for treating conditions characterized by the presence of an inflammatory component. MSCs can also have a reparative effect through paracrine signaling by releasing biologically active molecules that affect cell migration, proliferation, and survival of the surrounding cells.

The involvement of MSCs in the wound-healing process is critical, in particular for difficult nonhealing wounds resulting from trauma, diabetes, vascular insufficiency, and numerous other conditions. MSCs have a role in the inflammatory, proliferative, and remodeling phases of wound healing, and their presence supports healthy physiologic functioning towards successful healing. As such, therapeutic application of MSCs has been shown to enhance and improve wound healing in clinical settings.

Although bone marrow is one of the most frequently used and most readily available sources of MSCs, they are present throughout the body and have been isolated from adipose tissue, periosteum, tendon, muscle, synovial membrane, skin, and others [9]. In spite of the differences in gene...
and cytokine expression that can be observed in MSCs derived from different origins [10, 11], a set of core gene expressions are preserved [12] and MSCs from different tissues share properties, allowing identification of these cells as MSCs [13]. Moreover, at the present time there are no data points showing an advantage of a particular tissue origin of MSCs for wound healing or for other clinical applications. One source that has recently become a target for research and use is the human placenta. Comparison between bone marrow-derived MSCs and placental-derived MSCs showed minimal differences of cell phenotype, differentiation, and immunomodulative properties [14–17]. Like MSCs from other sources, placental MSCs are immune-privileged, allowing for allogeneic use [18, 19].

In this review, the role of MSCs in wound healing is examined, specifically for complex nonhealing wounds. In particular, the important role MSCs have in each phase of the wound-healing process is described. The use of allogeneic MSCs in placental-derived tissue for the treatment of wounds is also described.

**Three Phases of Normal Wound Healing**

*Normal wound healing is a dynamic and complex process involving a series of coordinated events, including bleeding and coagulation, acute inflammation, cell migration, proliferation, differentiation, angiogenesis, re-epithelialization, and synthesis and remodeling of ECM. These complex events occur in three overlapping phases: (a) inflammatory, (b) proliferative, and (c) remodeling.*

**Inflammatory**

Immediately after injury, coagulation and hemostasis serve to minimize blood loss from the wound site. The coagulation cascade is activated through extrinsic and intrinsic pathways, leading to platelet aggregation and clot formation [20]. While hemostasis is achieved, the inflammation phase begins. Neutrophils are the predominant cell type present 24–36 hours after injury. Guided by chemokines and other chemotactic agents (transforming growth factor-β [TGF-β], formylmethionyl peptides produced by bacteria, and others), neutrophils move from the circulating blood into the wound environment through the processes of margination and diapedesis [21]. The neutrophils remove foreign material, bacteria, dead cells, and damaged ECM by phagocytosis [22]. Mast cells are also active and release granules filled with enzymes, histamine, and other active amines. These mediators are responsible for the characteristic signs of inflammation around the wound site: rubor (redness), calor (heat), tumor (swelling), and dolor (pain) [23].

Monocytes, the precursors to macrophages, appear in the wound 48–72 hours after injury and continue the process of phagocytosis [24]. They are attracted to the wound site by a myriad of chemoattractive agents, such as clotting factors, platelet-derived growth factor (PDGF), TGF-β, and elastin and collagen breakdown products [25]. Macrophages also act as key regulatory cells and produce numerous potent tissue growth factors, including TGF-β, tumor necrosis factor-α (TNF-α), heparin binding epidermal growth factor, and fibroblast growth factor (FGF) [26]. These factors are integral in activating keratinocytes, fibroblasts, and endothelial cells [22].

**Proliferative**

The proliferative phase typically starts on the third day after the initial insult and lasts for about 2 weeks. It is characterized by fibroblast migration, deposition of newly synthesized extracellular matrix, and an abundant formation of granulation tissue [22]. The TGF-β released earlier by platelets and macrophages is a critical signal, as it increases the overall production of matrix components, including collagen, proteoglycans, and fibronectin [24]. At the same time TGF-β decreases the secretion of proteases responsible for the breakdown of the matrix and stimulates the production of tissue inhibitor of metalloproteinases (TIMP) [26]. Other cytokines considered to be important during this phase are interleukins, FGFs, and TNF-α. During the proliferation phase, the process of epithelialization is stimulated by the presence of epidermal growth factor (EGF) that is produced by platelets and keratinocytes and TGF-α that is produced by activated wound macrophages [27].

Local factors in the wound microenvironment (low pH, reduced oxygen tension, and increased lactate) initiate angiogenesis [28]. Angiogenesis is stimulated by vascular endothelial cell growth factor (VEGF), basic fibroblast growth factor (bFGF), and TGF-β produced by epidermal cells, fibroblasts, macrophages, and vascular endothelial cells [28].

In the proliferative phase, fibroblasts produce the new matrix needed to restore the structure of the injured tissue. Fibroblasts attach to the fibrin matrix and begin to produce collagen (predominantly type I) [29]. As the collagen matures, more and more intramolecular and intermolecular cross-links are created, serving to increase the strength of the weak tissue.

**Remodeling**

Remodeling is the final phase of wound healing. This phase may last 1–2 years or even longer [25]. The remodeling of an acute wound is designed to maintain a balance between degradation and synthesis, resulting in collagen bundles increasing in diameter and hyaluronic acid and fibronectin being degraded. The tensile strength of the wound increases progressively in parallel with collagen deposition [30]. Gradually, the activity of TIMPs increases, resulting in a drop in activity of metalloproteinase enzymes and an increase in new matrix accumulation [31]. Although the initial deposition of collagen bundles is highly disorganized, the new collagen matrix becomes more oriented and cross-linked over time. Its subsequent organization is achieved during the remodeling phase at the same time as wound contraction that has already begun in the proliferative phase. The underlying connective tissue shrinks in size and brings the wound margins closer together. The process is regulated by a number of factors, with PDGF, TGF-βs, and FGFs being the most important [32]. Finally, as the wound heals, the density of fibroblasts and macrophages is reduced by apoptosis. With time, the growth of capillaries stops, blood flow to the area declines, and metabolic activity decreases, resulting in a fully healed wound [22].

**Nonhealing, Chronic Wounds**

Chronic wounds are those that fail to progress through the three normal stages of healing, resulting in a tissue injury that is not repaired within the typical time period. Chronic wounds result from various underlying disorders, including diabetes, pressure, vascular insufficiency, burns, and vasculitis [23]. The healing process can be disturbed by various factors, which prolong one or more phases of inflammation, proliferation, or remodeling. These factors include one or more of the following: infection,
THE MECHANISMS OF MSCS IN THREE PHASES OF WOUND HEALING

MSCs are involved in all three phases of wound healing to varying degrees (Fig. 1). They also influence the wound’s ability to progress beyond the inflammatory phase and not regress to a chronic wound state. A significant component of the mechanism of action of MSCs is that they directly attenuate inflammatory response. Studies have shown that the addition of MSCs to an active immune response decreases secretion of the proinflammatory cytokines TNF-α and interferon-γ (IFN-γ) while simultaneously increasing the production of anti-inflammatory cytokines interleukin-10 (IL-10) and IL-4 [35]. It is these anti-inflammatory properties of MSCs that make them particularly beneficial to chronic wound treatment, as they can restart healing in stalled wounds by advancing the wound past a chronic inflammatory state into the next stage of healing. Accumulated data indicate the importance of MSC anti-inflammatory and immunomodulative activities in wound healing, detailed mechanisms of which are described in several reviews [36, 37].

At the present time it is recognized that MSCs have antimicrobial activity, which is critical for wound clearance from infection. MSC antimicrobial activity is mediated by two mechanisms: direct, via secretion of antimicrobial factors such as LL-37 [38], and indirect, via secretion of immunomodulative factors, which will upregulate bacterial killing and phagocytosis by immune cells [39].

MSCs in vivo can migrate to sites of injury in response to chemotactic signals modulating inflammation, repairing damaged tissue, and facilitating tissue regeneration [36]. Differentiation and paracrine signaling have both been implicated as mechanisms by which MSCs improve tissue repair. MSC differentiation contributes by regenerating damaged tissue, whereas MSC paracrine signaling regulates the local cellular responses to injury. Current data suggest that the contribution of MSC differentiation is limited due to poor engraftment and survival of MSCs at the site of injury. MSC paracrine signaling is likely the primary mechanism for the beneficial effects of MSCs on wounds, that is, to reduce inflammation, promote angiogenesis, and induce cell migration and proliferation [40].

Analyses of MSC-conditioned medium indicate that MSCs secrete many known mediators of tissue repair including growth factors, cytokines, and chemokines, specifically VEGF, PDGF, bFGF, EGF, keratinocyte growth factor (KGF), and TGF-β [40, 41]. Studies indicate that many cell types, including epithelial cells, endothelial cells, keratinocytes, and fibroblasts, are responsive to MSC paracrine signaling, which regulates a number of different cellular responses including cell survival, proliferation, migration, and gene expression [42]. MSC-conditioned medium acts as a chemoattractant for macrophages, endothelial cells, epidermal keratinocytes, and dermal fibroblasts in vitro [41, 43]. The presence of either MSCs or MSC-conditioned medium has been shown to promote dermal fibroblasts to accelerate wound closure [44]. MSCs also secrete mitogens that stimulate proliferation of keratinocytes, dermal fibroblasts, and endothelial cells in vitro [44, 45]. Further investigation has shown that dermal fibroblasts secrete increased amounts of collagen type I and alter gene expression in response to either MSCs in coculture or MSC-conditioned medium [44]. Overall, these data suggest that MSCs release soluble factors that stimulate proliferation and migration of the predominant cell types in the wound. In addition, the paracrine signaling of MSCs provides antiscarring properties through the secretion of VEGF and hepatocyte growth factor (HGF) and maintaining the proper balance between TGF-β3 and TGF-β3 [46–48]. The molecular mechanisms of MSC involvement in wound healing are complex, and further details of these processes can be found in recent reviews [49, 50].

Figure 1. Mesenchymal stem cell roles in each phase of the wound-healing process. Abbreviations: HGF, hepatocyte growth factor; IL, interleukin; KGF, keratinocyte growth factor; MMP, matrix metalloproteinase; PDGF, platelet-derived growth factor; TGF, transforming growth factor; TIMP, tissue inhibitor of metalloproteinases; TNF, tumor necrosis factor; VEGF, vascular endothelial growth factor.
Evidence of MSC Importance in Healing

In vivo studies have also demonstrated the advantages of using exogenous MSCs for the treatment of wounds. Several studies have shown that the administration of MSCs to either acute or diabetic wounds in rodents improves wound closure by accelerating epithelialization, increasing granulation tissue formation, and increasing angiogenesis. Nakagawa et al. [51] suggested that MSCs, together with bFGF in a skin defect model, accelerate wound healing and showed that the human MSCs transdifferentiated into the epithelium in rats. Shumakov et al. [52] showed that the transplantation of MSCs on the surface of deep burn wounds in rats decreased inflammatory cell infiltration and accelerated the formation of new vessels and granulation tissue. The cells were also shown to produce bioactive substances that seemed to accelerate the regeneration process. Collectively, these data demonstrate that MSC treatment impacts all phases of wound repair, including inflammation, epithelialization, granulation tissue formation, and tissue remodeling.

Clinical results using MSCs to enhance the healing of wounds have also been promising, and selected key studies are outlined in Table 1. In a human study of chronic nonhealing wounds, Badiavas and Falanga [53] showed that direct application of bone marrow-derived cells can lead to wound closure and rebuilding of tissues. One study of chronic diabetic foot ulcers by Vojtassák et al. [54] combined autologous fibroblasts and MSCs on a biodegradable collagen membrane. In the same study, MSCs were also injected into the edges of the wound on days 7 and 17. The wound size decreased, and the vascularity of the dermis and dermal thickness of the wound increased. A unique delivery system using fibrin glue was investigated in both acute and chronic wounds by Falanga et al. [55]. Bone marrow-derived MSCs combined with a fibrin spray were applied topically up to 3 times. Surgical defects created from excision of nonmelanoma skin cancers healed within 8 weeks, suggesting that MSCs contributed to accelerated resurfacing. Chronic lower-extremity wounds present for longer than 1 year significantly decreased in size or healed completely by 20 weeks. The study also found a correlation between the surface density of MSCs and the reduction in ulcer size. One of the largest series by Yoshikawa et al. [56] consisted of 20 patients with various nonhealing wounds that were treated with autologous bone marrow-derived MSCs cultured on a collagen sponge. Ninety percent of the wounds healed completely when treated with the cell composite.

Table 1. Selected key clinical studies using mesenchymal stem cells for the treatment of wounds

<table>
<thead>
<tr>
<th>Investigators/ sponsor</th>
<th>Wound type</th>
<th>Cell type</th>
<th>Administration details</th>
<th>Number of patients</th>
<th>Phase</th>
<th>Outcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Badiavas et al. 2003 [53]</td>
<td>Various chronic wounds</td>
<td>Fresh BM aspirate Cultured adherent BM cells</td>
<td>Fresh BM aspirate injected into wound; 3 additional topical applications of cultured cells</td>
<td>3</td>
<td>Case studies</td>
<td>All wounds healed with 3 applications or fewer</td>
</tr>
<tr>
<td>Falanga et al. 2007 [55]</td>
<td>Acute surgical</td>
<td>Cultured and profiled BM-MSCs</td>
<td>Topically suspended in fibrin spray</td>
<td>5</td>
<td>Case studies</td>
<td>All acute wounds closed by 8 weeks</td>
</tr>
<tr>
<td>Yoshikawa et al. 2008 [56]</td>
<td>Intractable dermatopathies</td>
<td>Cultured BM-MSCs</td>
<td>MSCs on collagen sponges used as wound dressings</td>
<td>20</td>
<td>Case studies</td>
<td>Wound healed in 18 of the 20 patients</td>
</tr>
<tr>
<td>Dash et al. 2000 [57]</td>
<td>Nonhealing ulcer or lower extremities</td>
<td>Cultured autologous BM-MSCs</td>
<td>Single intramuscular injection and topical application on wound with standard wound care or standard wound care alone</td>
<td>24</td>
<td>Randomized controlled study</td>
<td>By 12 weeks: Improvement in pain-free walking Ulcer size decreased by 72% in MSC-treated group</td>
</tr>
<tr>
<td>Lu et al. 2011 [58]</td>
<td>Diabetic critical limb ischemia with foot ulcers</td>
<td>Cultured autologous BM-MSCs</td>
<td>Single intramuscular injection of cells or normal saline control</td>
<td>41</td>
<td>Randomized controlled study</td>
<td>Improvement in painless walking time in MSC-treated group Fastest rate of healing in MSC treated group</td>
</tr>
<tr>
<td>Anterogen Co., Ltd.</td>
<td>Complex perianal fistulas</td>
<td>Fresh uncultured BM-mononuclear cells</td>
<td>Cell suspension in fibrin glue injected into wound</td>
<td>25</td>
<td>Phase II</td>
<td>Ongoing</td>
</tr>
<tr>
<td>Qingdao University Ruhr University of Bochum</td>
<td>Diabetic foot ischemia</td>
<td>Umbilical cord MSCs</td>
<td>Multiple intramuscular injections</td>
<td>50</td>
<td>Phase I–II</td>
<td>Ongoing</td>
</tr>
<tr>
<td>Stempeutics Research Pvt. Ltd.</td>
<td>Diabetics with chronic limb ischemia</td>
<td>BM-MSCs</td>
<td>Intramuscular injections or intra-arterial injections</td>
<td>30</td>
<td>Phase II</td>
<td>Ongoing</td>
</tr>
<tr>
<td>Franziskus Krankenhaus</td>
<td>Critical limb ischemia</td>
<td>Adult allogenic MSCs</td>
<td>Intramuscular injection</td>
<td>20</td>
<td>Phase I–II</td>
<td>Ongoing</td>
</tr>
<tr>
<td></td>
<td></td>
<td>BM-MSCs</td>
<td>Intramuscular injection</td>
<td>90</td>
<td>Phase II–III</td>
<td>Ongoing</td>
</tr>
</tbody>
</table>

Abbreviations: BM, bone marrow; MSC, mesenchymal stem cell.
graft, and the addition of MSCs facilitated tissue regeneration.

Systemic administration of MSCs has also been observed to promote healing in chronic wounds, particularly when there is an underlying condition such as diabetes and other systemic disorders. In a randomized controlled study of 24 patients with nonhealing ulcers of lower extremities by Dash et al. [57], the authors simultaneously administered cultured autologous bone marrow-derived MSCs intramuscularly into the affected limb and topically directly onto the ulcer. Within 12 weeks, significant improvement in pain and a greater decrease in wound size (72% versus 25%) were observed in the MSC-treated group compared to the control group. Clinical benefit of systemic administration of MSCs was also observed in a randomized controlled study conducted by Lu et al. [58]. Briefly, one limb of the patient was injected intramuscularly with cultured autologous bone marrow-derived MSCs or fresh nonculture bone marrow-derived mononuclear cells. The contralateral leg was injected with normal saline as a control for each patient. Compared to control groups, both MSCs and mononuclear cell injections resulted in marked improvement in pain-free walking at 24 weeks and significant increase in ulcer healing rate. Furthermore, the MSC-treated group demonstrated significantly greater increase in ulcer healing rate compared to the mononuclear-injected group.

Altogether, these clinical results suggest that MSCs provide clinical benefits when treating chronic wounds either topically or systemically. Although these studies have shown promising results, there are still numerous areas of future study including the effect of the source of the MSCs, the benefits of MSCs alone or within a matrix, the timing and frequency of MSC administration, and the number of cells administered.

**MSCs FROM PLACENTAL TISSUE IN WOUND HEALING**

The use of placental tissue for wound treatment started more than 100 years ago [59, 60]. The first reported case series used amnion membrane (AM) and chorionic membrane (CM) as skin substitutes for burned and ulcerated surfaces [61–63]. More recently, placental tissue has been studied as an alternative source of MSCs, providing multipotent differentiation and beneficial immunosuppressive capabilities similar to MSCs derived from other tissues. Miao et al. [15] compared placental-derived MSCs with bone marrow-derived MSCs in terms of morphology, growth, membrane markers, and differentiation potential. MSCs from placenta presented the same morphology and growth characteristics, as well as markers such as CD105, CD29, and CD44. There was no expression detected of the hematopoietic markers CD34, CD45, and HLA-DR. The authors also demonstrated differentiation potential of placental MSCs into endothelial and neuronal cells.

Other studies have confirmed the presence of cell markers commonly found in MSC populations in cells derived from placental membranes. Specifically, CD44, CD73, CD90, and CD105 membrane markers were identified [64]. Additional studies have demonstrated trilineage differentiation capabilities of placental-derived MSCs [65–67], as well as their lack of immunogenicity and positive immunomodulatory effects in vitro [18].

The beneficial activity of MSCs in wound healing is complemented by the effects of growth factors and ECM produced by the native placenta tissue cells. Analysis of cryopreserved AM growth factor and growth factor receptor content by reverse transcriptase-polymerase chain reaction and enzyme-linked immunosorbent assay have identified EGF, KGF, HGF, bFGF, and the family of TGFs [68]. As previously described, these factors are critical in the wound-healing process.

Research on the properties of AM and CM tissue and improved understanding of the MSC constituents have led to renewed interest in their clinical use. A recent report on the treatment of venous leg ulcers with allogeneic AM transplantation highlights the antiadhesive, wound protection, and proper re-epithelialization (antiscarring) effects as extremely beneficial in serious wounds [69]. Allogeneic transplants for wound healing are a significant improvement over autologous skin grafts that require inconvenient harvesting with frequent morbidity.
Table 2. Functional classes of wound healing proteins in human mesenchymal stem cell-containing skin substitutes

<table>
<thead>
<tr>
<th>Specific proteins</th>
<th>Primary function</th>
</tr>
</thead>
<tbody>
<tr>
<td>TIMP-1 and MMP2</td>
<td>Matrix and growth factor degradation, facilitate cell migration</td>
</tr>
<tr>
<td>Ang-2, HB-EGF, EGF, FGF-7 (also known as KGF), PlGF, PEDF, TPO, TGF-α, IGF bFGF, PDGF AA, AB, and BB; VEGF, VEGF-C, and VEGF-D</td>
<td>Inhibit activity of MMPs, angiogenic</td>
</tr>
<tr>
<td>TGF-β3, HGF</td>
<td>Stimulate growth and migration</td>
</tr>
<tr>
<td>IFN-α2</td>
<td>Promote angiogenesis, also proliferative and migration</td>
</tr>
<tr>
<td>α2-Macroglobulin</td>
<td>stimulatory effects</td>
</tr>
<tr>
<td>Acrp-30</td>
<td>Inhibit fibrosis by decreasing TGF-β1 and TGF-β2</td>
</tr>
<tr>
<td>IL-1RA</td>
<td>Inhibit protease activity, coordinate growth factor bioavailability</td>
</tr>
<tr>
<td>N-GAL</td>
<td>Regulate growth and activity of keratinocytes</td>
</tr>
<tr>
<td>IL-13</td>
<td>Anti-inflammatory</td>
</tr>
<tr>
<td>LIF</td>
<td>Antibacterial</td>
</tr>
<tr>
<td>SDF-1β</td>
<td>Support of angiogenic growth factors</td>
</tr>
<tr>
<td>IGFBP1, 2, 3</td>
<td>Recruit cells to site of tissue damage</td>
</tr>
<tr>
<td></td>
<td>Regulate IGF and its proliferative effects</td>
</tr>
</tbody>
</table>

Abbreviations: Acrp-30, adiponectin; Ang-2, angiotensin-2; bFGF, basic fibroblast growth factor; EGF, epidermal growth factor; FGF, fibroblast growth factor; HGF, hepatocyte growth factor; IFN, interferon; IGF, insulin-like growth factor; IGFBP, insulin-like growth factor binding protein; IL, interleukin; KGF, keratinocyte growth factor; LIF, leukemia inhibitory factor; MMP, matrix metalloproteinase; N-GAL, neutrophil gelatinase-associated lipocalin; PDGF, platelet-derived growth factor; PEDF, pigment epithelium-derived factor; PlGF, placenta growth factor; SDF, stem cell-derived factor; TGF-α, transforming growth factor-α; TIMP, tissue inhibitor of matrix metalloproteinase; TPO, thrombopoietin; VEGF, vascular endothelial growth factor.

Human MSC-containing skin substitutes

Human MSC-containing skin substitutes derived from placental tissues are an attractive source of MSCs to lead to improved wound-healing therapies, in particular for the treatment of chronic wounds and burns. Skin substitutes based on cryopreserved placental membranes must be processed to selectively remove antigenic components and preserve the tissue’s native ECM architecture, growth factors, and cytokines as well as high-potential cells, including MSCs, which promote the complex sequence of events required for physiologic wound healing.

Human MSC-containing skin substitutes have been characterized to identify key components necessary for proper wound healing [70]. A unique feature of these skin substitutes is the presence of viable cells, including MSCs, fibroblasts, and epithelial cells. Fluorescence-activated cell sorting analysis of cells within the skin substitutes reveals the expression of MSC markers, CD105 and CD166, and the absence of CD45, confirming their stem cell identity. Because CD45-positive cells are potentially immunogenic, the absence of this antigen indicates a lack of cell-mediated immunogenicity. The exact number of MSCs present within the skin substitute is unpublished. However, for a reference point, the published cell concentration within placental membranes ranges from 1 to 4 × 10⁶ cells/cm² [16, 71]. The viability of cells is also confirmed, ensuring that functioning cells are delivered at the time of use. Post-thaw, the product’s cell viability must be determined to be greater than 70% before it can be released for clinical use. Figure 2A illustrates in situ staining showing the high density of viable cells in the layers of the human MSC-containing skin substitutes. Although the presence of viable MSCs within the skin substitute is beneficial for wound repair in that the cells actively produce tissue reparative paracrine factors [72, 73], it is the combination of viable MSCs, native ECM, and growth factors within the skin substitute that is integral in promoting wound repair.

A protein profile of the skin substitute reveals the presence of an extensive array of beneficial proteins, which include physiologic growth factors needed to carry out the phases of normal healing—inflammatory, proliferative, and remodeling (Table 2). Several anti-inflammatory and antimicrobial factors are present in the placental-derived MSC-containing skin substitute including defensins, N-GAL, IL-1RA, and several others [70]. These factors help to transit from the inflammatory phase to the proliferative phase of wound healing as well as to clear infected wounds. Other key proteins present within the skin substitute are the angiogenic proteins VEGF, bFGF, and PDGF; the epithelial cell stimulatory proteins KGF and EGF; and the antiscarring proteins TGF-β3, IFN-α2, and HGF. As described previously, physiologic levels of growth factors and cytokines are critical to ensure healing of chronic wounds. Reombinant growth factors used to treat chronic wounds undergo rapid degradation and require repeated administration of nonphysiologically high concentrations of growth factors to support healing of chronic wounds, which may lead to adverse side effects [74, 75]. However, the unique population of viable cells allows for the sustained release of a cocktail of growth factors, persisting at physiological levels over extended periods of time (Fig. 2B) and eliminating the need for frequent reapplication. Functionally, the skin substitutes have been shown to promote cell migration and wound closure in in vitro wound-healing assays [70].

Conclusion

Wound healing is a complex process that requires the coordinated interplay of ECM, growth factors, and cells. MSCs, in particular, play an important role in mediating each phase of the wound-healing process—inflammatory, proliferative, and remodeling. During the inflammatory phase, MSCs coordinate the effects of inflammatory cells and inhibit the deleterious effects of inflammatory cytokines such as TNF and IFN-γ. In addition, MSCs support wound clearance from infection via direct secretion of antimicrobial factors and by stimulating phagocytosis by immune cells. The ability of MSCs to promote the transition from the inflammatory to the proliferative phase is particularly critical for treating chronic wounds where high levels of inflammation prevent healing. MSCs also contribute to the proliferative phase.
by expressing growth factors such as VEGF, bFGF, and KGF to promote granulation and epithelialization. Lastly, MSCs regulate remodeling of the healed wound by promoting organized ECM deposition. As such, the benefits of MSCs in wound healing have been demonstrated in several preclinical and clinical studies. Thus, multiple mechanisms are involved in MSC-mediated wound healing, including antiinflammatory and antimicrobial, immunomodulative, and tissue reparative activities.

Although numerous products are currently available to treat wounds, very few therapies exist that incorporate the beneficial effects of MSCs, which are especially critical for difficult-to-heal wounds. Many efforts are under way to develop novel bioengineered wound-healing products, and considering the role of MSCs in the wound-healing process, it is important to consider their inclusion.

ACKNOWLEDGMENTS
The authors thank Chris Alder, Erica Elchin, and Dayna Healy for their insightful review and comments.

AUTHOR CONTRIBUTIONS
S.M., E.A.L., D.Y., A.D.-M.: conception and design, manuscript writing; M.A.L.: conception and design, final approval of manuscript.

REFERENCES
9. da Silva Meirelles L, Caplan AI, Nardi NB. In search of the in vivo identity of mesenchymal stem cells. STEM CELLS 2008;26:2287–2299.


